Convergent Genetic and Expression Datasets Highlight TREM2 in Parkinson’s Disease Susceptibility
- 446 Downloads
A rare TREM2 missense mutation (rs75932628-T) was reported to confer a significant Alzheimer’s disease (AD) risk. A recent study indicated no evidence of the involvement of this variant in Parkinson’s disease (PD). Here, we used the genetic and expression data to reinvestigate the potential association between TREM2 and PD susceptibility. In stage 1, using 10 independent studies (N = 89,157; 8787 cases and 80,370 controls), we conducted a subgroup meta-analysis. We identified a significant association between rs75932628 and PD (P = 3.10E-03, odds ratio (OR) = 3.88, 95 % confidence interval (CI) 1.58–9.54) in No-Northern Europe subgroup, and significantly increased PD risks (P = 0.01 for Mann–Whitney test) in No-Northern Europe subgroup than in Northern Europe subgroup. In stage 2, we used the summary results from a large-scale PD genome-wide association study (GWAS; N = 108,990; 13,708 cases and 95,282 controls) to search for other TREM2 variants contributing to PD susceptibility. We identified 14 single-nucleotide polymorphisms (SNPs) associated with PD within 50-kb upstream and downstream range of TREM2. In stage 3, using two brain expression GWAS datasets (N = 773), we identified 6 of the 14 SNPs regulating increased expression of TREM2. In stage 4, using the whole human genome microarray data (N = 50), we further identified significantly increased expression of TREM2 in PD cases compared with controls in human prefrontal cortex. In summary, convergent genetic and expression datasets demonstrate that TREM2 is a potent risk factor for PD and may be a therapeutic target in PD and other neurodegenerative diseases.
KeywordsTREM2 rs75932628 Parkinson’s disease Alzheimer’s disease Genome-wide association study
This work was supported by funding from the National Nature Science Foundation of China (Grant No. 81300945 and 81471294).
Conflict of interest
The authors reported no potential conflicts of interest.
- 2.Lill CM, Rengmark A, Pihlstrom L, Fogh I, Shatunov A, Sleiman PM, Wang LS, Liu T et al (2015) The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimers DementGoogle Scholar
- 7.Liu G, Li F, Zhang S, Jiang Y, Ma G, Shang H, Liu J, Feng R et al. Analyzing large-scale samples confirms the association between the abca7 rs3764650 polymorphism and alzheimer's disease susceptibility. Mol Neurobiol 2014Google Scholar
- 8.Chen H, Wu G, Jiang Y, Feng R, Liao M, Zhang L, Ma G, Chen Z et al (2014) Analyzing 54,936 samples supports the association between cd2ap rs9349407 polymorphism and Alzheimer's disease susceptibility. Mol NeurobiolGoogle Scholar
- 21.Roussos P, Katsel P, Fam P, Tan W, Purohit DP, Haroutunian V (2014) The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. Alzheimers DementGoogle Scholar
- 22.Lue LF, Schmitz CT, Serrano G, Sue LI, Beach TG, Walker DG (2014) Trem2 protein expression changes correlate with Alzheimer's disease neurodegenerative pathologies in post-mortem temporal cortices. Brain PatholGoogle Scholar
- 24.Strobel S, Grunblatt E, Riederer P, Heinsen H, Arzberger T, Al-Sarraj S, Troakes C, Ferrer I et al (2015) Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPARgamma. J Neural TransmGoogle Scholar
- 26.Feng SJ, Nie K, Gan R, Huang J, Zhang YW, Wang LM, Zhao JH, Tang HM et al (1780) Triggering receptor expressed on myeloid cells 2 variants are rare in Parkinson's disease in a Han Chinese cohort. Neurobiol Aging 2014(35):e1711–1782Google Scholar
- 27.Chen Y, Chen X, Guo X, Song W, Cao B, Wei Q, Ou R, Zhao B et al (2015) Assessment of TREM2 rs75932628 association with Parkinson's disease and multiple system atrophy in a Chinese population. Neurol SciGoogle Scholar